A pharmacist-led collaborative drug therapy management program at NYC Health + Hospitals/Bellevue reported high patient satisfaction, and every surveyed patient said they felt respected and supported by their pharmacist.
|Articles|October 14, 2021
Daily OTC Pearl: Bismuth Subsalicylate (Pepto Bismol)
Author(s)Saro Arakelians, PharmD
Bismuth subsalicylate comes as a liquid, tablet, or chewable tablet to treat diarrhea and the symptoms of an upset stomach.
Advertisement
OTC/Lifestyle Pearl of the Day: Bismuth Subsalicylate (Pepto Bismol)
Indication: Bismuth subsalicylate is used to treat diarrhea in adults and teenagers.
Insight:
- Bismuth subsalicylate is also used to relieve the symptoms of an upset stomach, such as heartburn, indigestion, and nausea in adults and teenagers.
- This medicine should not be used in children younger than 12 years of age.
- In some patients, bismuth subsalicylate may cause dark tongue and/or grayish black stool. This is only temporary and will go away when use of the medication is stopped.
- Bismuth subsalicylate comes as a liquid, tablet, or chewable tablet to be taken by mouth, with or without food.
- Swallow the tablets whole and do not chew them.
- Shake the liquid well before each use to mix the medication evenly.
- Drink plenty of water or other beverages to replace fluids that may be lost while having diarrhea.
- Dosing:
- Shake before use.
- Use dose cup or tablespoon.
- For adults and children 12 years of age and older: 1 dose (30 ml or 2 TBSP) every half hour to 1 hour as needed.
- Do not exceed 8 doses (240 ml or 16 TBSP) in 24 hours.
Sources:
Advertisement
Related to this article
A Novo Nordisk-funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, though the findings cannot show causation.
Invasive pneumococcal disease may be the first sign of undiagnosed blood cancers and antibody deficiencies in adults, a new study finds.
A new analysis finds a significant weight loss edge for tirzepatide under one estimand but not another; no head-to-head trial exists at these doses.
In SCOUT-HCM, mavacamten reduced the Valsalva LVOT gradient by 48 mm Hg versus placebo in adolescents. REMS, echo monitoring, and CYP interactions still apply in the new population.
Indirect comparison links orforglipron 17.2 mg to 1.5% more weight loss and 0.3% more A1C lowering than oral semaglutide 25 mg in adults with type 2 diabetes.
Pharmacists can help overcome influenza vaccine hesitancy by correcting common misconceptions, routinely asking every patient about vaccination, and leveraging their standing as trusted health care professionals.
Phase 3 TRIUMPH-2 data presented at EASD show HbA1C reductions up to 1.6%, with GI effects, hypotension, and dysesthesia as key counseling points.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Tirzepatide Linked to More Weight Loss Than Semaglutide 7.2 mg
2
September 2026 in Pain Management: 4 Updates on Treatment and Pharmacy Practice
3
Pharmacist, Advocate, Ally: Delivering Comprehensive Gender-Affirming Care
4
Pharmacists Can Close CKD Medication Adherence Gaps, PHTI Says
5